Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum

Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum

BACKGROUND Generation of potent anti-HIV antibody responses in mucosal compartments is a potential requirement of a transmission-blocking HIV vaccine. HIV-specific, functional antibody responses are present in breast milk, and these mucosal antibody responses may play a role in protection of the majority of HIV-exposed, breastfeeding infants. Therefore, characterization of HIV-specific antibodi...

Human Ig Loci from Transgenic Mice Expressing Neutralizing Activity Against HIV-1 Monoclonal Antibodies with Efficient Isolation of Novel Human

Expressing Human Ig Loci Activity Against HIV-1 from Transgenic Mice Monoclonal Antibodies with Neutralizing Efficient Isolation of Novel Human

Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.

The genes encoding broadly HIV-1-neutralizing human monoclonal antibodies (MAbs) are highly divergent from their germ line counterparts. We have hypothesized that such high levels of somatic hypermutation could pose a challenge for elicitation of the broadly neutralizing (bn) Abs and that identification of less somatically mutated bn Abs may help in the design of effective vaccine immunogens. I...

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies

The recent discoveries of broadly potent neutralizing human monoclonal antibodies represent a new generation of antiretrovirals for the treatment and prophylaxis. Antibodies are generally considered more effective and safer and have been proved to provide passive protection against mucosal challenge in humanized mice and macaques. Several neutralizing Abs could protect animals against HIV-1 but...